← Eichor
Study identifier: NCT06112704 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors

Condition: Advanced Solid Tumor  ·  Sponsor: Hansoh BioMedical R&D Company

PhasePhase 2
Planned participants220
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

HS-20093 is a humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the anti-tumor activity, safety, pharmacokinetics and immunogenicity of HS-20093 in Chinese advanced esophageal carcinoma and other solid tumor patients.

This description comes directly from the study's public registry record.

Talk to the study team

Yun Sun  ·  18321785381  ·  suny20@hspharm.com

Always discuss trial participation with your own doctor first.

Locations (21)

Anhui Provincial Cancer HospitalHefei, Anhui, ChinaRecruiting
Fujian Provincial Tumor HospitalFujian, Fujian, ChinaNot Yet Recruiting
The 900th Hospital of the Joint Service Support Force of the Chinese People's Liberation ArmyFuzhou, Fujian, ChinaRecruiting
Guangdong Provincial People's HospitalGuangzhou, Guangdong, ChinaRecruiting
Harbin Medical University Cancer HospitalHarbin, Heilongjiang, ChinaRecruiting
Tumour Hospital of Anyang cityAnyang, Henan, ChinaRecruiting
The First Affiliated Hospital of Henan University of Science & TechnologyLuoyang, Henan, ChinaRecruiting
Nanyang Central HospitalNanyang, Henan, ChinaRecruiting
The First Affiliated Hospital of Xinxiang Medical UniversityXinxiang, Henan, ChinaRecruiting
Henan Cancer HospitalZhengzhou, Henan, ChinaRecruiting
The First Affiliated Hospital of Zhengzhou UniversityZhengzhou, Henan, ChinaRecruiting
Tongji Hospital, affiliated with Tongji Medical College, Huazhong University of Science and TechnologyWuhan, Hubei, ChinaRecruiting

+ 9 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06112704